A Phase III Randomized Parallel-Group Multicenter Trial, Designed to Compare 5 Years of Adjuvant Exemestane Versus 5 Years of Observation in Postmenopausal Women With Operable Breast Cancer Who Have Received 5-7 Years of Adjuvant Tamoxifen.
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Exemestane (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms ATENA
- 25 Dec 2008 New trial record.